GoodRx Holdings Inc. (GDRX), a publicly-traded company listed on the NASDAQ, operates one of America's leading digital platforms dedicated to transforming the healthcare industry by providing consumer access to affordable and convenient healthcare services. Largely focused on the prescription drug market, GoodRx is on a mission to bring transparency and greater cost-efficiency to healthcare consumers.
Founded in 2011 and headquartered in Santa Monica, California, GoodRx began as a price comparison tool for prescription medications. By compiling data from over 70,000 U.S. pharmacies, the platform enables consumers to get their needed prescriptions at the cheapest possible prices. It serves millions of Americans, empowering them to save money on prescription and over-the-counter medications.
But it's not just about cost-savings. GoodRx understands that the healthcare journey can be complex and stressful, which is why they've built multichannel offerings to provide consumers with value-added services. These include telehealth services and personalized medical information content. Through its web and mobile platforms, consumers are not just getting affordable medications; they are also getting access to healthcare providers online, via a platform that is as transparent as it is easy-to-use.
GoodRx's business model works by partnering with pharmaceutical manufacturers, insurance companies, and healthcare providers. These partnerships allow them to provide discounts on prescription medication. It offers free coupons that can be used at participating pharmacies to get discounts on prescription medications. The company earns revenue each time one of these coupons is used.
Despite its relatively short operating history, GoodRx has made a significant impact in the U.S healthcare sector. It has helped Americans save up to $30 billion on prescription medical costs, a significant achievement reflecting its commitment to reshaping the healthcare experience.
GoodRx went public with an IPO in September 2020, marking a significant milestone in its trajectory. The company raised around $1 billion from the IPO, underscoring investors' confidence in its model and mission.
Steered by co-founders, Doug Hirsch, and Trevor Bezdek, GoodRx continues to innovate and push the boundaries of what's possible in the healthcare space. The company, under their leadership, is committed to creating better health outcomes for Americans by making healthcare more affordable and accessible. GoodRx is undoubtedly a transformative force in the American healthcare landscape, and it seems set to continue expanding its services and influence for years to come.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
GoodRx CFO Justin Fengler reported the vesting of restricted stock units (RSUs) and the corresponding share withholding for tax liabilities on September 15, 2026. This involved two separate RSU awards, totaling 3,087 shares vested and 1,354 shares withheld for taxes at $3.56 per share. After these transactions, Fengler directly held 52,509 shares of Class A Common Stock, with additional RSUs remaining from both awards.
GoodRx Chief Accounting Officer Thomas Chan reported the vesting of 2,101 restricted stock units (RSUs) into Class A Common Stock on September 15, 2026. Simultaneously, 1,069 shares were withheld at $3.56 each to cover tax liabilities. Following these transactions, Chan directly owns 14,578 shares of Class A Common Stock and beneficially owns 12,606 remaining RSUs, with the RSU award vesting quarterly until fully vested.
Francisco Partners, a 10% owner of GoodRx Holdings (NASDAQ: GDRX), sold approximately $4.2 million worth of Class A Common Stock between August 19 and August 21, 2026, at prices ranging from $3.4968 to $3.5299 per share. These sales coincided with other transactions including the conversion of Class B to Class A shares and pro rata distributions to partners. Separately, GoodRx recently raised its full-year 2026 revenue outlook after exceeding second-quarter expectations, driven by growth in Pharma Direct and subscription revenues, despite a decrease in monthly active consumers as the company shifts its business model.
GoodRx Holdings Inc. has filed a Form 3 for its CFO and Chief Strategy & Operations Officer, Justin Fengler, designating him as a new insider. The filing discloses that Fengler directly holds 23,651 Class A shares as of August 6. This news brief was generated by Public Technologies using AI, based on original content filed by GoodRx via EDGAR.